MEGIN

MEGIN operates in the specialist neurotechnology and medical-device market, with a focus on magnetoencephalography (MEG) for clinical brain mapping and neuroscience research. Its offering spans TRIUX neo hardware, MEG Maps workflow software, and MEGreview analysis tools, alongside installation, maintenance, training, and customer support. This end-to-end scope distinguishes its stated approach from a hardware-only proposition, while its 2026 collaboration with BESA signals an emphasis on connecting acquisition and analysis workflows through an open platform architecture. The July 2026 dual-MEG installation at Tsinghua also demonstrates an application beyond individual-patient mapping: synchronized measurement of two participants for social neuroscience. The company’s categories include Health Care, Medical Device, Manufacturing, and Product Design. Available company information does not identify distinct competitor names, so a direct competitor ranking is not supportable. Its relative position is best understood as a specialized MEG systems provider rather than a broad neuroimaging or general medical-device company.

MEGIN’s growth signals are more evident in product and partnership development than in disclosed financing. In 2026, the company announced two notable ecosystem milestones: an expanded BESA partnership on May 12, 2026 to develop an open MEG Maps architecture, and a dual-TRIUX neo hyperscanning facility with Aalto University and Tsinghua University on Jul 8, 2026. MEG Maps was described as commercially available in the United States and Japan, with EU MDR review underway for European commercialization. These steps mark a shift toward combining MEG hardware with software workflows and specialized research installations. The company is listed in the 51–100 employee range, while its website describes a team of more than 70 across the United States, United Kingdom, Finland, and Japan. The evidence supports ongoing product and geographic activity, not a quantified growth rate.